Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

QLT Inc.’s (QLTI - Analyst Report) second quarter 2013 loss of 11 cents per share was narrower than the year-ago loss of 25 cents per share and the Zacks Consensus Estimate of a loss of 12 cents. The narrower loss was due to the lower costs incurred by QLT in the second quarter of 2013.

QLT did not report any revenues during the second quarter of 2013. We note that QLT’s product portfolio previously included eye-drug Visudyne. In Sep 2012, QLT sold its Visudyne business to Valeant Pharmaceuticals International, Inc. (VRX - Snapshot Report).
    
Previously, QLT had an agreement with Novartis (NVS - Snapshot Report) for the commercialization of Visudyne in ex-U.S. territories. Visudyne is used for treating abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration.

Research and development expenses at QLT came in at $4.4 million in the second quarter of 2013 compared with $7.5 million in the year-ago quarter. The reduction was due to the cost savings from the restructuring schemes and the completion of some early-stage pipeline programs. Selling, general and administrative expense plummeted to $1.8 million in the second quarter of 2013 from $5.9 million a year ago. The decrease was primarily attributable to cost savings from the restructurings announced by QLT in 2012.

Earlier in the year, QLT completed the sale of its punctal plug drug delivery system technology to Mati Therapeutics Inc. Mati was founded by Robert Butchofsky, an ex-president and chief executive officer of QLT .

QLT, which focuses on developing and commercializing innovative ocular products for those with high unmet medical needs, carries a Zacks Rank #3 (Hold). Companies like Questcor Pharmaceuticals, Inc. (QCOR - Analyst Report) appear to be more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%